GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (FRA:UR9) » Definitions » 5-Year Yield-on-Cost %

Clinuvel Pharmaceuticals (FRA:UR9) 5-Year Yield-on-Cost % : 0.94 (As of Dec. 13, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals 5-Year Yield-on-Cost %?

Clinuvel Pharmaceuticals's yield on cost for the quarter that ended in Jun. 2024 was 0.94.


The historical rank and industry rank for Clinuvel Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:

FRA:UR9' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.12   Med: 0.28   Max: 0.94
Current: 0.94


During the past 13 years, Clinuvel Pharmaceuticals's highest Yield on Cost was 0.94. The lowest was 0.12. And the median was 0.28.


FRA:UR9's 5-Year Yield-on-Cost % is ranked worse than
67.92% of 159 companies
in the Biotechnology industry
Industry Median: 1.58 vs FRA:UR9: 0.94

Competitive Comparison of Clinuvel Pharmaceuticals's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinuvel Pharmaceuticals's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's 5-Year Yield-on-Cost % falls into.



Clinuvel Pharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Clinuvel Pharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Clinuvel Pharmaceuticals  (FRA:UR9) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Clinuvel Pharmaceuticals 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals Business Description

Address
535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Clinuvel Pharmaceuticals Headlines

No Headlines